|
Item 2.04
|
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
|
As previously reported, on April 7, 2016,
Navidea Biopharmaceuticals, Inc. (the “Company”) received a notice from Capital Royalty Partners II L.P., as Secured
Party and as Control Agent, Capital Royalty Partners II – Parallel Fund “A” L.P., as Secured Party, and Parallel
Investment Opportunities Partners II L.P., as Secured Party (collectively, “CRG”), pursuant to the Term Loan Agreement,
dated May 8, 2015, as amended by Amendment 1 to Term Loan Agreement, dated as of December 23, 2015 (as amended, the “Loan
Agreement”), by and among the Company, the subsidiary guarantors from time to time party thereto and CRG. In the notice,
CRG claimed that certain Events of Default, unrelated to repayment terms, had occurred under the Loan Agreement and that CRG, as
a result, was entitled to certain remedies set forth in the Loan Agreement.
On April 28, 2016, the Company received
a further notice from CRG informing the Company that CRG commenced exercising its remedies, including with respect to cash collateral.
In that regard, CRG informed the Company that it had delivered notices to exercise control of the Company’s accounts pursuant
to the blocked account control and pledge collateral account control agreements with CRG. On May 2, 2016, the Company sought a
temporary restraining order in Harris County Court, Texas, enjoining CRG from causing any further “freeze” of the Company’s
accounts and requiring CRG to restore the accounts to the position they were in prior to CRG’s April 28, 2016 acts, pending
a more complete review of the Company’s and CRG’s positions in the lawsuit. On May 19, 2016, a hearing was held and
on May 24, 2016, the court denied the Company’s request for temporary injunctive relief.
The Company is maintaining its position
that the alleged claims do not constitute Events of Default under the Loan Agreement and intends to vigorously defend against these
claims. The Company continues to evaluate its options, including the possible assertion of counterclaims.
The Company has set up alternative banking
arrangements so that it may continue to function during the pendency of this case. While the Company expects CRG to attempt to
gain and exercise control over these alternative banking arrangements, the Company believes that it has defenses against such actions.
The Company is also continuing its efforts to obtain alternative financing arrangements in order to refinance the CRG debt. While
the Company believes that the actions of CRG are a violation of the Loan Agreement, there can be no assurance that CRG will not
prevail in exercising control over any banking arrangements that the Company creates or that the Company will be able to refinance
the CRG debt.
Statements contained or incorporated by
reference in this Current Report on Form 8-K which relate to other than strictly historical facts, such as statements about the
Company’s plans and strategies, expectations for future financial performance, new and existing products and technologies,
and markets for the Company’s products, are forward-looking statements. The words “believe,” “expect,”
“anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements
that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could
cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited
to, the Company’s continuing operating losses, ability to repay debt, the outcome of the CRG litigation, uncertainty of market
acceptance, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence
on limited product line and distribution channels, competition, limited marketing and manufacturing experience, and other risks
detailed in the Company’s most recent Annual Report on Form 10-K and other filings with the United States Securities and
Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements.